WO2004089410A1 - 神経因性疼痛の予防及び/または治療剤 - Google Patents
神経因性疼痛の予防及び/または治療剤 Download PDFInfo
- Publication number
- WO2004089410A1 WO2004089410A1 PCT/JP2004/004758 JP2004004758W WO2004089410A1 WO 2004089410 A1 WO2004089410 A1 WO 2004089410A1 JP 2004004758 W JP2004004758 W JP 2004004758W WO 2004089410 A1 WO2004089410 A1 WO 2004089410A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- cyclic
- compound
- Prior art date
Links
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 66
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 65
- 230000003449 preventive effect Effects 0.000 title claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 84
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 80
- 230000003042 antagnostic effect Effects 0.000 claims abstract description 39
- 102000004384 Histamine H3 receptors Human genes 0.000 claims abstract description 33
- 108090000981 Histamine H3 receptors Proteins 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 230000008485 antagonism Effects 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract description 4
- -1 cyclic alkyl Chemical group 0.000 claims description 72
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 64
- 125000000623 heterocyclic group Chemical group 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 43
- 125000003118 aryl group Chemical group 0.000 claims description 37
- 229940124597 therapeutic agent Drugs 0.000 claims description 35
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 29
- 125000004122 cyclic group Chemical group 0.000 claims description 27
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 24
- 125000002947 alkylene group Chemical group 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 125000004434 sulfur atom Chemical group 0.000 claims description 19
- QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical group C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 17
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 12
- 125000006848 alicyclic heterocyclic group Chemical group 0.000 claims description 11
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 11
- 102000000543 Histamine Receptors Human genes 0.000 claims description 10
- 108010002059 Histamine Receptors Proteins 0.000 claims description 10
- 125000004450 alkenylene group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000003435 aroyl group Chemical group 0.000 claims description 8
- 229960001340 histamine Drugs 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 7
- 125000001589 carboacyl group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 125000004419 alkynylene group Chemical group 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 125000005103 alkyl silyl group Chemical group 0.000 claims description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 3
- 125000000732 arylene group Chemical group 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000005549 heteroarylene group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 44
- 208000000114 Pain Threshold Diseases 0.000 description 42
- 230000037040 pain threshold Effects 0.000 description 42
- 238000012360 testing method Methods 0.000 description 37
- 208000028389 Nerve injury Diseases 0.000 description 31
- 230000008764 nerve damage Effects 0.000 description 31
- 208000002193 Pain Diseases 0.000 description 25
- 230000036407 pain Effects 0.000 description 21
- 229940126062 Compound A Drugs 0.000 description 20
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 10
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 10
- 229960001052 streptozocin Drugs 0.000 description 10
- 239000002904 solvent Substances 0.000 description 8
- 208000004454 Hyperalgesia Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 206010053552 allodynia Diseases 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000001061 Dunnett's test Methods 0.000 description 4
- UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- PTKHFRNHJULJKT-UHFFFAOYSA-N jnj-5207852 Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN1CCCCC1 PTKHFRNHJULJKT-UHFFFAOYSA-N 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Chemical class 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940121914 Histamine H3 receptor agonist Drugs 0.000 description 2
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 208000004404 Intractable Pain Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003382 histamine H3 receptor agonist Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- XNQIOISZPFVUFG-RXMQYKEDSA-N (R)-alpha-methylhistamine Chemical compound C[C@@H](N)CC1=CN=CN1 XNQIOISZPFVUFG-RXMQYKEDSA-N 0.000 description 1
- ITOJPDNONZGUKB-UHFFFAOYSA-N 1-[5-(4-nitrophenoxy)pentyl]pyrrolidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCCCCCN1CCCC1 ITOJPDNONZGUKB-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 1
- DOPOFWDDERLSPU-UHFFFAOYSA-N 3-(1h-imidazol-5-yl)propyl n'-[(4-chlorophenyl)methyl]-n-cyclohexylcarbamimidothioate Chemical class C1=CC(Cl)=CC=C1CNC(SCCCC=1N=CNC=1)=NC1CCCCC1 DOPOFWDDERLSPU-UHFFFAOYSA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- LMKPPWNWUJXSAQ-UHFFFAOYSA-N 5-[3-(4-ethynylphenoxy)propyl]-1h-imidazole Chemical compound C1=CC(C#C)=CC=C1OCCCC1=CNC=N1 LMKPPWNWUJXSAQ-UHFFFAOYSA-N 0.000 description 1
- ZAGFXUMBSUVWFZ-UHFFFAOYSA-N 5-[3-[4-(trifluoromethyl)phenoxy]propyl]-1h-imidazole Chemical compound C1=CC(C(F)(F)F)=CC=C1OCCCC1=CNC=N1 ZAGFXUMBSUVWFZ-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 102000004187 Histamine H4 receptors Human genes 0.000 description 1
- 108090000796 Histamine H4 receptors Proteins 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- RZKYEQDPDZUERB-UHFFFAOYSA-N Pindone Chemical group C1=CC=C2C(=O)C(C(=O)C(C)(C)C)C(=O)C2=C1 RZKYEQDPDZUERB-UHFFFAOYSA-N 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000006356 alkylene carbonyl group Chemical group 0.000 description 1
- 125000006319 alkynyl amino group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical compound NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- ACQBHJXEAYTHCY-UHFFFAOYSA-N cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone Chemical compound C=1C=C(OCCCC=2NC=NC=2)C=CC=1C(=O)C1CC1 ACQBHJXEAYTHCY-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-M oxalate(1-) Chemical compound OC(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-M 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005494 pyridonyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a preventive and / or therapeutic agent for neuropathic pain, comprising a compound having a histamine H3 receptor antagonistic activity as an active ingredient.
- Neuropathic pain is pathological and intractable pain due to peripheral or central nervous system dysfunction, as opposed to sensation or acute pain as a vital signal that protects the body from injury or harm. It is known that neuropathic pain is caused by neuropathy caused by trauma, surgery, infection with herpes virus or AIDS virus, metabolic abnormalities such as cancer or diabetes, and the mechanism of its development is unknown. It is thought to be caused by functional and plastic changes in the peripheral or central nervous system.
- the treatment of neuropathic pain includes nerve block therapy, electrical stimulation therapy, antiepileptic drugs, anticonvulsants, non-steroidal anti-inflammatory analgesics, and other drug therapies. There are few examples showing remarkable effects except for the effects and the like, and development of effective therapeutic agents for neuropathic pain is desired.
- histamine receptor has four subtypes of H1, H2, H3, and H4 receptors.
- Histamine H3 receptor is discovered by Arrang et al 198 years [Neichiya (Nature), 1983 years, 302 vol, 832- 837 pp, cloning in 1999 was made [Molecular 'Pharmacology (Molecular Pharmacology) s 1999, Vol. 55, pp. 01-1107].
- the histamine H3 receptor is expressed in the sensory nerve, spinal cord and central nervous system, and regulates the release of neurotransmitters as o-trecept or hetero-recept.
- histamine H3 receptor antagonists Alzheimer's disease, eating disorders, sleep disorders, attention deficit hyperactivity disorders, and the like are assumed to be indicated as indications for histamine H3 receptor antagonists (EP09832300).
- histamine H3 receptor antagonists are associated with acute nociceptive pain [e.g., British Journal of Pharmacology (British Journal of Pharmacology) cology, 111 Vol., P.1269-1279; Pharmacology 'No ⁇ ; Io Chemistry' and Behavior-Ichi (Pharmacology, Biochemistry and Behavior) ⁇ 2002, Vol. 72, p.751-760], Histamine H3
- Histamine H3 There is no report on the relationship between receptor antagonists and neuropathic pain.
- An object of the present invention is to provide a preventive and / or therapeutic agent for neuropathic pain, comprising a compound having a histamine H3 antagonistic activity as an active ingredient.
- the present invention relates to the following (1) to (24).
- An agent for preventing and / or treating neuropathic pain comprising as an active ingredient a compound having a histamine H3 receptor antagonistic activity or a pharmacologically acceptable salt thereof.
- R 1 and R 2 are the same or different and each represent a hydrogen atom, a substituted or unsubstituted lower alkyl or a substituted or unsubstituted cyclic alkyl, or together with a nitrogen atom adjacent to R 1 and Forming a substituted or unsubstituted heterocyclic group,
- X represents an oxygen atom or a sulfur atom.
- the agent for preventing and / or treating ⁇ -induced pain according to the above (1) which is a compound represented by the following formula (1):
- R 1 and ⁇ is a hydrogen atom, the other is a substituted or unsubstituted lower alkyl or a substituted or unsubstituted cyclic alkyl, and X is a sulfur atom.
- W is a group that imparts a histamine H3 receptor antagonistic activity and / or an activity when bound to the 4- or 5-position of the imidazole ring
- R 3 and R 4 are the same or different and each represents a substituted or unsubstituted lower alkyl or a substituted or unsubstituted cyclic alkyl, or R 3 and ⁇ together with an adjacent nitrogen atom are substituted or Which forms an unsubstituted heterocyclic group)
- R 5 represents lower alkyl, cyclic alkyl, aryl, aralkyl, lower alkanol, cyclic alkanol, aroyl, lower alkoxycarbonyl or aminoalkylcarbonyl).
- R s , R 7 , R 8 , R 9 and R 1Q are the same or different and each represents a hydrogen atom, a halogen, an amino, a nitro, a cyano, a substituted or unsubstituted lower alkyl, a substituted or unsubstituted lower alkyl, Represents an alkoxy, a substituted or unsubstituted lower alkanol, a substituted or unsubstituted cyclic alkanol, a substituted or unsubstituted aroyl or a substituted or unsubstituted lower alkanoylamino,
- nl represents an integer of 1 to 7).
- W is the formula (V) (V) (Wherein, R 8a has the same meaning as the above, and nla has the same meaning as the above-mentioned nl).
- the method for preventing neuropathic pain according to any one of the above (5) to (8), / Or therapeutic agent.
- z represents a substituted or almost unsubstituted lower alkylene
- Q 1 represents a sulfur atom, -NH- or -C3 ⁇ 4-,
- R n s R 13 and R 15 are the same or different and each represents a hydrogen atom, a lower alkyl, cyclic alkyl, represents substitution or unsubstituted Ariru or substituted or unsubstituted Ararukiru, R 12 is a hydrogen atom, a lower alkyl, cyclic alkyl alkyl, substituted or unsubstituted ⁇ Li Lumpur, substituted or unsubstituted Ararukiru or formula (VII) n one 2, one 16 (VII)
- n2 represents an integer of 1 to 4, and ⁇ 16 represents lower alkyl, cyclic alkylalkyl or substituted or unsubstituted aralkyl).
- R 14 represents a hydrogen atom, a halogen, an amino, a nitro, a cyano, a substituted or unsubstituted lower alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl;
- a 1 represents a bond or a carbonyl
- a z represents an oxygen atom or a sulfur atom
- L 1 represents a fluorine atom or a lower alkylene which may be substituted by hydroxy
- P 1 and P 2 represent a hydrogen atom or together represent a bond
- I represents a hydrogen atom or lower alkyl) or -N (R 27 )-(where 7 represents a hydrogen atom, lower alkyl or lower alkanol)
- R 25 represents a cyclic alkyl or aryl.
- L 3 represents a cyclic alkylene, an arylene, a divalent group formed by removing one arbitrary hydrogen atom from an alicyclic heterocyclic group or a heteroarylene, and is a bond, an oxygen atom, a sulfur atom, a lower alkylene.
- R 2i and R 22 are the same or different and represent a hydrogen atom, lower alkyl, hydroxy lower alkyl, cyclic alkyl, cyclic alkyl alkyl, lower alkenyl, lower alkynyl, aryl, aralkyl, heterocyclic group or heterocyclic alkyl, R 21 and R 22 together with an adjacent nitrogen atom form a substituted or unsubstituted nitrogen-containing heterocyclic group, I is a hydrogen atom, halogen, nitro, hydroxy, mercapto, cyano, carboxy, lower alkoxycarbonyl, lower alkanol, lower alkanoyloxy, lower alkylsulfinyl, lower alkylsulfonyl, lower alkylthio, aryl, complex group, substitution or unsubstituted lower alkyl, substituted or unsubstituted lower an alkoxy, -NR 29a 29 b (wherein R 29a and R 29 b are respectively the same
- the compound having histamine receptor antagonistic activity is represented by the formula (Villa)
- the preventive and / or therapeutic agent for neuropathic pain according to the above (1), which is a compound represented by the formula (ABT-239):
- n3a is 1 or 2
- H 33a is a hydrogen atom, amino, lower alkyl, lower alkoxy, cyclic alkoxy, substitution Or unsubstituted cyclic alkyl, substituted or unsubstituted aryl, substituted or unsubstituted aryloxy, substituted or unsubstituted heterocyclic group or
- E 34 ⁇ 5 a and 6 a are the same or different and each represent a hydrogen atom or a lower alkyl]], a group represented by the formula (XI),
- L 5 represents a bond, a lower alkylene which may be substituted by a substituted or unsubstituted aryl,
- L 6 represents a bond, substituted or unsubstituted lower alkylene or substituted or unsubstituted cyclic alkylene, but L 5 and L 6 do not represent a bond at the same time,
- ⁇ Represents an oxygen atom, a sulfur atom, -S (0)-, -S (0) 2 -or -C ⁇ C-,
- I is halogen, amino, cyano, aminocarbonyl, cyclic alkyl, lower alkoxy, lower alkanol, cyclic alkanol, lower alkoxycarbonyl, mono or di-lower alkylaminocarbonyl, aralkyl, aroyl, arylsulfonyl, aromatic Heterocyclic carbonyl, aromatic heterocyclic sulfonyl, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted aromatic heterocyclic group, -CHR 4Qa- (m 41a (wherein, R 4Qa Represents a hydrogen atom, lower alkyl, cyclic alkyl, cyclic alkylalkyl, aryl or aralkyl, fi 41a represents a hydrogen atom, lower alkyl, dialkyl, cyclic alkylalkyl, lower alkanoyl, lower alkoxycarbony
- I and IP are the same or different and are a hydrogen atom, halogen, amino, nitro, azido, hydroxy, cyano, formyl, carboxy, lower alkyl, perfluoro lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy or perfluoro lower alkoxy Or the compound of the formula (1), wherein R 31 and-represent -0G3 ⁇ 4C (0)- ⁇ .
- the preventive and / or therapeutic agent for neuropathic pain according to (1) which is a compound represented by the following formula (A-304121):
- the prophylactic and / or therapeutic agent for neuropathic pain according to the above (1), which is a compound represented by the following formula (A-317920):
- R 42a and R 42b are the same or different and represent lower alkyl, lower alkenyl, cyclic alkyl or cyclic alkylalkyl, or H 42a and H 42b together with an adjacent nitrogen atom form a nitrogen-containing heterocyclic group;
- Two of ⁇ , R 4 and R 45 are the same or different and represent a hydrogen atom or a halogen, and the other one is a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted heterocyclic alkyl, a substituted or unsubstituted Heterocyclic alkenyl, substituted or unsubstituted heterodialkynyl, -L 7 -L 8 -Q 4 wherein L 7 represents a bond or an oxygen atom, L 8 is substituted or unsubstituted lower alkylene, cyclic alkylene, Represents alkenylene or alkynylene, and Q 4 represents an aliphatic heterocyclic group or Volume 46 (wherein R 46a and R 4sb are the same or different and represent a hydrogen atom, lower alkyl, lower alkenyl, cyclic alkyl, cyclic alkylalkyl , Aralkyl, aralkyl, a heterocyclic
- Ring alkyl R 49 represents a hydrogen atom, a halogen, a hydroxy or a lower alkoxy), and is a compound represented by the above formula (1).
- a compound having histamine receptor antagonism is represented by the formula (XlVa):
- the preventive and / or therapeutic agent for neuropathic pain according to the above (1), which is a compound represented by the following formula (JNJ-5207852):
- (21) A method for preventing and / or treating neuropathic pain, comprising a step of administering an effective amount of a compound having a histamine H3 receptor antagonistic action.
- halogen represent each atom of fluorine, chlorine, bromine and iodine.
- the lower alkyl includes, for example, linear or branched alkyl having 1 to 10 carbon atoms, and specifically, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl , Isopentyl, neopentyl, hexyl, heptyl, octyl, isooctyl, nonyl, decyl and the like.
- the lower alkyl moiety in lower alkoxy, lower alkoxycarbonyl, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, mono- or di-lower alkylaminocarbonyl and tri-lower alkylsilyl has the same meaning as the above lower alkyl.
- the two lower alkyl moieties in the di-lower alkylaminocarbonyl and the three lower alkyl moieties in the tri-lower alkylsilyl may be the same or different.
- alkylene moiety in lower alkylene, hydroxy lower alkyl, cyclic alkylalkyl, aminoalkylcarbonyl, aralkyl and heterocyclic alkyl has the same meaning as the above lower alkyl in which one hydrogen atom has been removed.
- cyclic alkyl examples include a cyclic alkyl having 3 to 8 carbon atoms, and specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- the cyclic alkyl moiety in the cyclic alkylalkyl, the cyclic alkoxy, the cyclic alkanol and the cyclic alkylsulfonyl has the same meaning as the above-mentioned cyclic alkyl.
- Cyclic alkylene has the same meaning as the above-mentioned cyclic alkyl except for removing one hydrogen atom.
- the lower alkenyl includes, for example, straight-chain or branched alkenyl having 2 to 6 carbon atoms, and more specifically, pinyl, aryl, probenyl, methyl acryl, clotyl, 1-butenyl, 3-butenyl , 2-pentenyl, 4-pentenyl, 2-hexenyl, 5-hexenyl and the like.
- alkenylene moiety in lower alkenylene and heterocyclic alkenyl has the same meaning as the above-mentioned lower alkenyl obtained by removing two hydrogen atoms.
- lower alkynyl examples include straight-chain or branched alkynyl having 2 to 6 carbon atoms, and more specifically, ethynyl, provinyl, butynyl, pentynyl, hexynyl and the like.
- alkynylene moiety in lower alkynylene and complex alkynyl has the same meaning as the above-mentioned lower alkynyl except for removing one hydrogen atom.
- lower alkanoyl moiety of lower alkynyl, lower alkynylamino and lower alkynyloxy examples include straight-chain or branched alkanols having 1 to 7 carbon atoms, more specifically formyl, acetyl, Propionyl, Petilil, A Sobutyryl, valeryl, isovaleryl, vivaloyl, hexanoyl, heptanyl and the like.
- the alkylenecarbonyl moiety in the heterocyclic alkyl group has the same meaning as the above-mentioned lower alkyl group obtained by removing one hydrogen atom.
- aryl examples include aryl having 6 to 14 carbon atoms, and specific examples include phenyl, naphthyl, and anthryl.
- aryl part in aralkyl, aryloxy, aryloyl and arylsulfonyl has the same meaning as the above aryl.
- Arylene has the same meaning as the above aryl except for removing one hydrogen atom.
- heterocyclic group examples include an aromatic aromatic group, an alicyclic heterocyclic group and the like.
- heterocyclic group part in heterocyclic alkyl, heterocyclic alkenyl, heterocyclic alkynyl, heterocyclic carbonyl, heterocyclic alkanoyl and heterocyclic sulfonyl has the same meaning as the above-mentioned heterocyclic group.
- aromatic heterocyclic group examples include a 5- or 6-membered monocyclic aromatic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and a 3- to 8-membered heterocyclic group.
- the part of the aromatic heterocyclic group in the aromatic heterocyclic carbonyl and the aromatic heterocyclic sulfonyl has the same meaning as the above-mentioned aromatic heterocyclic group.
- Heteroarylene has the same meaning as the above aromatic heterocyclic group obtained by removing one hydrogen atom.
- Examples of the alicyclic heterocyclic ring include a 5- or 6-membered monocyclic alicyclic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, a 3- to 8-membered ring And a condensed alicyclic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like.
- the alicyclic heterocyclic group moiety in the divalent group formed by removing one arbitrary hydrogen atom from the alicyclic heterocyclic group has the same meaning as the above-mentioned alicyclic heterocyclic group.
- a nitrogen-containing heterocyclic group formed together with an adjacent nitrogen atom and a heterocyclic group formed together with an adjacent carbon atom and a nitrogen atom include, for example, at least one nitrogen atom A 3- to 9-membered monocyclic heterocyclic group (the monocyclic heterocyclic group may contain another nitrogen atom, oxygen atom or sulfur atom), or a bicyclic ring in which a 3- to 8-membered ring is fused Or a tricyclic heterocyclic group containing at least one nitrogen atom (the condensed heterocyclic group may contain another nitrogen atom, oxygen atom or sulfur atom) and the like.
- the substituents in the substituted heterocyclic group formed together with the group and adjacent carbon and nitrogen atoms may be the same or different, for example, halogen, amino, azide, nitro, hydroxy having 1 to 8 substituents.
- Perfluoro-lower alkyl and perfluoro-lower alkoxy are lower alkyl and lower alkoxy, respectively, in which all hydrogen atoms are substituted by fluorine atoms.
- W may be any group that imparts histamine H3 receptor antagonistic activity and / or action when bound to position 4 or 5 of imidazolone II.
- Pharmaceutically acceptable salts of compounds (1), (11), (VIX (VlliX (IX) and (XIV)) include pharmacologically acceptable acid addition salts, metal salts, ammonium salts, and organic amines. Includes addition salts, amino acid addition salts and the like.
- the pharmacologically acceptable acid addition salts of compounds (1), (11), (VI) ⁇ (VI II), (IX) and (XIV) include hydrochloride, sulfate, nitrate, phosphate And organic salts such as acetates, maleates, fumarates, and citric acid.
- Pharmacologically acceptable metal salts include alkali salts such as sodium salts and potassium salts.
- Metal salts, magnesium salts, alkaline earth metal salts such as calcium salts and the like, aluminum salts, zinc salts and the like.
- Examples of pharmacologically acceptable ammonium salts include salts such as ammonium and tetramethylammonium.
- organic amine addition salts include addition salts such as morpholine and piperidine, and pharmacologically acceptable amino acid addition salts include glycine, phenylalanine, and the like. Lysine, Asparagine Include addition salts such as glutamic acid. Hisumin, an active ingredient of the preventive and / or therapeutic agent for neuropathic pain of the present invention
- the compound having an H3 antagonistic action is not limited as long as it has a histamine H3 receptor antagonistic action, and may be, for example, a peptide compound or a non-peptide compound.
- Neuropathic pain causes illnesses such as trauma, compression, surgery, infection with herpes virus, AIDS virus, etc., and metabolic disorders such as cancer, diabetes, etc., resulting in peripheral or central nervous system disorders.
- the result is chronic, intractable pain caused by some dysfunction.
- narcotics such as strangulation neuropathy, phantom limb pain, postoperative neuralgia, post-herpetic pain, thalamic pain after stroke, neural back pain, spinal cord injury, trigeminal neuralgia, glossopharyngeal neuralgia, and morphine
- Symptoms include, but are not limited to, for example, burning pain, oral denia (feeling severe pain to non-noxious stimuli), hyperalgesia, and the like.
- the neuropathic pain model includes rats with neuropathic pain caused by nerve injury, strangulated nerve injury rats, and neuropathic pain caused by diabetes. Pain pain [Pain
- gabapentin a spasmolytic drug
- neuropathic pain postherpetic neuralgia, neural back pain, and diabetic neuralgia
- test compounds used in the evaluation of the inhibitory effect of hissamine H3 receptor antagonist on neuropathic pain were thioperamide, compounds A ⁇ A-304121, A-317920, ABT-239, JNJ-5027852, and clopenpropit.
- Compound A is compound 43 [N- ⁇ 3- (4-cyanophenoxy) propyl ⁇ diethylamine hydrogen oxalate] described in EP0982300.
- Test Example 1 Neuropathic pain-suppressing effect of drug in rats with strangulated nerve injury (1) The experiment was performed by the method of T. Mosconi, L. Kruger et al. [Pain, 1996, Vol. 64, p. 37-57], according to the method of GM Pitcher et al. [Pain, 1999, Vol. 83, p.37-46].
- the above-mentioned von Frey filament was used for the measurement of allodynia or hyperalgesia characteristic of neuropathic pain.
- the nociceptive threshold is determined by the WJ Dixon's up-down method [Annual Review-Off ', "Famacao” and “Toxico” (Annual Review of Pharmacology and Toxicology), 1980, Volume 20, p.441 -462]. Rats were placed in stainless steel cages (750 width x 210 depth x 170 mm height) and pain thresholds were measured after acclimatization to the environment for at least 20 minutes. The pain threshold of normal rats was around 10 g, and a decrease in pain threshold was observed in the operative side paws of rats with strangulated nerve injury.
- the pain threshold was measured before drug administration, 30 minutes after administration, 1 hour after, 1.5 hours after, and 2 hours after administration.
- the test compound was suspended in distilled water and administered intraperitoneally at a volume of 2 mL / kg.
- Figure 1, Figure 2, Figure 3, Figure 4, Figure 5 and Figure 6 show thioperamide, compound A, A-304121, A-317920, ABT for lowering the pain threshold (Arodenia) in rats with strangulated nerve injury.
- -239 and JJU-5207852 are shown.
- Thioperamide, Compounds A A-30412 A-317920, ABT-239, and JNJ-5207852 ameliorated the decrease in the pain threshold of the operative foot in rats with strangulated nerve injury.
- Test Example 2 Neuropathic pain-suppressing effect of Jai in rats with strangulated nerve injury (2) Rats with strangulated nerve injury were prepared in the same manner as in Test Example 1, and after preparation, 14-21 The test was performed.
- the measurement of cold-stimulated allodynia was performed according to the method of Choi et al. (Pain, 1994, Vol. 59, pp. 369-376).
- the constriction nerve injury rod is placed in an acrylic cage (width 900 x depth 210 x height 140 mm) with a metal mesh set at the bottom, and after acclimating to the environment for at least 20 minutes, about 30 ⁇ L of acetone is applied to the left foot. It was applied to the back of the hind limb (close to the heel), and the escape response (licking, pumbling, and shaking) was measured.
- Acetone was applied 5 times at 5 minute intervals, and individuals who showed an escape reaction of 4 times or more were regarded as pathological conditions, and the drug was administered.
- Test Example 1 the test compound was suspended in distilled water to give a 2 mL / kg The dose was administered intraperitoneally.
- FIG. 7 shows the results of administering Compound A to cold-stimulated allodynia in rats with constrictive nerve injury.
- Compound A reduced the number of withdrawal reactions and ameliorated the cold-stimulated allodynia found in constriction nerve injury rats.
- Test Example 3 Drug-induced neuropathic pain suppression in streptozotocin-induced diabetic pain rat
- the experiment was performed according to the method of N. A. Calcutt et al. [British Journal of Pharmacology] 1997, Vol. 122, .1478-1482. Streptozotocin was administered intraperitoneally to male SD rats at a dose of 60 mg / kg to produce streptozotocin-induced diabetic pain rats. Only animals with a blood glucose level of 250 mg / dl or more 6 weeks after administration and a 50-reaction threshold value of 4 g or less measured with the von Frey filament described above were used for the experiment. Pain thresholds were measured after the rats were placed in stainless steel cages (750 x 210 x 170 cm) and allowed to acclimatize for at least 20 minutes.
- the pain level of rats to which streptozotocin was not administered was about 10 g, and a clear decrease in pain threshold was observed in diabetic rats to which streptozotocin was administered.
- the administration conditions were the same as in Test Example 1, in which the test compound was suspended in distilled water and administered intraperitoneally at a volume of 2 mL / kg. .
- FIGS. 8, 9 and 10 show the results of thioperamide, compound A and A-304121 on the reduction of the pain threshold in streptozotocin-induced diabetic pain rats.
- Thioperamide, Compound A and A-304121 improved the decrease in the pain threshold observed in streptozotocin-induced diabetic pain rate.
- Test Example 4 Neuropathic pain-suppressing action of drug in rats with a constriction nerve injury (3) A constriction nerve injury rat was prepared in the same manner as in Test Example 1, and the following 14 to 21 days after preparation, The test by intraventricular administration was performed according to the method.
- the guide cannula is a stainless steel tube with a length of 21 AW, an outer diameter of 0.8 orchid, and an inner diameter of 0.5 AW. It was adjusted to protrude one marauder from the tip of the guide cannula. Insert the guide cannula into the left ventricle and secure it to the skull with dental acrylic cement. Specified. Rats were allowed to recover for 3 days to 1 week after surgery.
- test compound was dissolved in physiological saline and administered intracerebroventricularly in a volume of 10 j.
- FIG. 11, FIG. 12 and FIG. 13 show the effects of clobenpropit, compound A and A-304121 on the reduction of pain threshold in rats with strangulated nerve injury.
- Clobenpropite, compounds A) and A-304121 improved the lowering of pain threshold seen in rats with constriction nerve injury.
- Test Example 5 The inhibitory effect of the drug on neuropathic pain in rats with strangulated nerve injury (4) To determine whether the ameliorating effect of pain by histamine receptor antagonist is histamine H3 receptor-mediated An antagonism experiment was performed. A constriction nerve injury rat was prepared in the same manner as in Test Example 1, and the test was performed by intraventricular administration in the same manner as in Test Example 4. The test compound was dissolved in physiological saline and administered intraventricularly in a volume of 10 jul. After measuring pain threshold, administer solvent (saline) or histamine H3 receptor agonist (R) -methylhistamine [Nature, 1987, Vol. 327, p. 117-123] After 15 minutes, a solvent (saline) or A-304121 was administered. Pain thresholds were measured 15 and 30 minutes after drug administration.
- the figure shows the effects of A-304121 and (R) -Hymethylhistamine on the reduction of pain threshold in rats with strangulated nerve injury.
- A-304121 improved the reduction in pain thresholds observed in rats with strangulated nerve injury.
- the action of A-304121 was suppressed.
- the administration route of the medicament of the present invention is not particularly limited, and it is possible to appropriately select the most effective administration route for prevention and / or treatment from either oral administration or parenteral administration such as intravenous administration. it can.
- formulations suitable for oral administration include tablets and the like, and examples of formulations suitable for parenteral administration include injections and the like. I can do it.
- solid preparations such as tablets, for example, lactose, excipients such as mannitol, disintegrants such as starch, lubricants such as magnesium stearate, binders such as hydroxypropyl cell mouth, fatty acid esters And a plasticizer such as glycerin.
- Formulations suitable for parenteral administration comprise sterile aqueous solutions containing the active compound, which is preferably isotonic with the blood of the recipient.
- a solution for injection is prepared using a carrier or the like comprising a salt solution, a glucose solution, or a mixture of saline and pudose solution.
- Auxiliary components can also be added.
- the dose and frequency of administration of the medicament of the present invention vary depending on the dosage form, the age and weight of the patient, and the nature or severity of the condition to be treated. kg, preferably 0.05 to 50 mg / k, is administered once or several times a day. However, these dosages and the number of administrations vary depending on the various conditions described above.
- FIG. 1 is a graph showing the effect of thioperamide on lowering the pain threshold (alodynia) in rats with strangulated nerve injury.
- the vertical axis represents the pain threshold (g), and the horizontal axis represents the time (unit: minute) after administration.
- FIG. 2 is a graph showing the effect of Compound A on lowering the pain threshold (Aroadenia) in rats with strangulated nerve injury.
- the vertical axis represents the pain threshold (g), and the horizontal axis represents the time (unit: minutes) after administration.
- FIG. 3 is a diagram showing the effect of A-304121 on lowering the pain threshold (Arodania) in rats with strangulated nerve injury.
- the vertical axis represents the pain threshold directly (g), and the horizontal axis represents the time after administration (unit: minutes).
- FIG. 4 shows the effect of A-317920 on lowering of pain threshold (Aroadenia) in rats with strangulated nerve injury.
- the vertical axis represents the pain threshold (g), and the horizontal axis represents the time (unit: minutes) after administration.
- FIG. 5 shows the effect of ABT-239 on lowering the pain threshold (Aroadenia) in strangulated nerve injury rats.
- the vertical axis represents the pain threshold (g), and the horizontal axis represents the time (unit: hours) after administration.
- FIG. 6 shows the effect of JNJ-5207852 on lowering the pain threshold (Alodenia) in rats with strangulated nerve injury.
- the vertical axis indicates the pain threshold (g), and the horizontal axis indicates the time (in hours) after administration.
- FIG. 7 is a graph showing the effect of compound A on cold-stimulated allodynia in rats with strangulated nerve injury.
- the vertical axis represents the number of withdrawal reactions, and the horizontal axis represents the time (unit: minutes) after administration.
- FIG. 8 is a graph showing the effect of thioperamide on the reduction of pain threshold in streptozotocin-induced diabetic pain rats.
- the vertical axis represents the pain threshold (g), and the horizontal axis represents the time (unit: minutes) after administration.
- FIG. 9 is a graph showing the effect of Compound A on decreasing the pain threshold in streptozotocin-induced diabetic pain rats.
- the vertical axis represents the pain threshold (g), and the horizontal axis represents the time (unit: minutes) after administration.
- One-one Compound A 10 mg / kg administration group
- FIG. 10 shows the effect of A-304121 on reducing pain threshold in streptozotocin-induced diabetic pain rats.
- the vertical axis represents the pain threshold (g), and the horizontal axis represents the time (unit: minutes) after administration.
- FIG. 11 shows the effect of clobenpropit on lowering the pain threshold (Alodenia) in rats with strangulated nerve injury.
- the vertical axis represents the pain threshold (g), and the horizontal axis represents the time (unit: minutes) after administration.
- Figure 12 shows the combination of a strangulated nerve injury rat with a decrease in pain threshold (Aroadenia). The effect of object A is shown.
- the vertical axis represents the pain threshold ( g ), and the horizontal axis represents the time (unit: minute) after administration.
- — ⁇ 1 Compound A 100 ⁇ g administration group
- FIG. 13 shows the effect of A-304121 on lowering the pain threshold (Alodenia) in rats with strangulated nerve injury.
- the vertical axis represents the pain threshold (g), and the horizontal axis represents the time (unit: minute) after administration.
- FIG. 14 shows the effect of A-304121 and R-(-)-hi-methyl-histamine on the reduction of pain threshold in rats with strangulated nerve injury.
- the vertical axis represents the pain threshold (g), and the horizontal axis represents the time (unit: minutes) after administration.
- a tablet having the following composition is prepared by a conventional method. 40 g of thioperamide, 286.8 g of lactose and 60 g of potato starch are mixed, and 120 g of a 10 ° aqueous solution of hydroxypropyl cellulose is added thereto. The mixture is kneaded by a conventional method, granulated and dried, and then sized to obtain granules for tableting. To this, 1.2 g of magnesium stearate was added and mixed, and the mixture was tableted with a tablet machine (RT-15 type, manufactured by Kikusui Co., Ltd.) having a punch with a diameter of 8 strokes to obtain tablets (20 mg of active ingredient per tablet). Containing) is obtained.
- RT-15 type manufactured by Kikusui Co., Ltd.
- a preventive and / or therapeutic agent for neuropathic pain comprising a compound having a histamine H3 receptor antagonistic activity or a pharmacologically acceptable salt thereof as an active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002521000A CA2521000A1 (en) | 2003-04-03 | 2004-04-01 | Preventive and/or therapeutic agent for neuropathic pain |
JP2005505233A JPWO2004089410A1 (ja) | 2003-04-03 | 2004-04-01 | 神経因性疼痛の予防及び/または治療剤 |
EP04725174A EP1611902A4 (en) | 2003-04-03 | 2004-04-01 | MEANS FOR THE PREVENTION AND / OR TREATMENT OF NEUROPATHIC PAIN |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-099785 | 2003-04-03 | ||
JP2003099785 | 2003-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004089410A1 true WO2004089410A1 (ja) | 2004-10-21 |
Family
ID=33156708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004758 WO2004089410A1 (ja) | 2003-04-03 | 2004-04-01 | 神経因性疼痛の予防及び/または治療剤 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1611902A4 (ja) |
JP (1) | JPWO2004089410A1 (ja) |
CA (1) | CA2521000A1 (ja) |
WO (1) | WO2004089410A1 (ja) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007043365A1 (ja) * | 2005-10-06 | 2007-04-19 | Japan Science And Technology Agency | 神経因性疼痛治療剤 |
US7396857B2 (en) | 2005-04-22 | 2008-07-08 | Wyeth | Therapeutic combinations for the treatment or prevention of depression |
WO2011083316A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives for the treatment of central nervous system disorders |
WO2011083314A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives for the treatment of central nervous system disorders |
WO2011083315A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Compounds and their use |
WO2011121309A1 (en) | 2010-03-31 | 2011-10-06 | Takeda Pharmaceutical Company Limited | Phenyl sulfonyl derivatives and their use as histamine h3 antagonists |
WO2013027001A1 (en) | 2011-08-22 | 2013-02-28 | Takeda Pharmaceutical Company Limited | Compounds and their use to treat histamine h3 related disorders |
US8569303B2 (en) | 2005-12-29 | 2013-10-29 | Celtaxsys, Inc. | Diamine derivatives as inhibitors of leukotriene A4 hydrolase |
US9777006B2 (en) | 2013-03-14 | 2017-10-03 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
US9822106B2 (en) | 2013-03-14 | 2017-11-21 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
US9856249B2 (en) | 2013-03-14 | 2018-01-02 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
US10350197B2 (en) | 2013-03-12 | 2019-07-16 | Celtaxsys, Inc. | Methods of inhibiting leukotriene A4 hydrolase |
US10450269B1 (en) | 2013-11-18 | 2019-10-22 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10898484B2 (en) | 2018-05-31 | 2021-01-26 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
US11053195B2 (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3003466B1 (fr) * | 2013-03-22 | 2015-08-07 | Servier Lab | Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001008705A1 (fr) * | 1999-08-02 | 2001-02-08 | Yamanouchi Pharmaceutical Co., Ltd. | Remedes contre les douleurs neurogenes |
WO2001014383A1 (fr) * | 1999-08-24 | 2001-03-01 | Toray Industries, Inc. | Remedes contre les douleurs neuropathiques et modeles animaux de douleurs neuropathiques |
US20010049367A1 (en) * | 2000-03-09 | 2001-12-06 | Bennani Youssef L. | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
WO2002012214A2 (en) * | 2000-08-08 | 2002-02-14 | Ortho Mcneil Pharmaceutical Inc. | Non-imidazole aryloxyalkylamines as h3 receptor ligands |
WO2002013821A1 (en) * | 2000-08-17 | 2002-02-21 | Gliatech, Inc. | Novel alicyclic imidazoles as h3 agents |
WO2002053153A1 (fr) * | 2000-12-28 | 2002-07-11 | Daiichi Pharmaceutical Co., Ltd. | Medicaments permettant de traiter et de prevenir une douleur neurologique |
JP2002521463A (ja) * | 1998-07-29 | 2002-07-16 | ソシエテ シヴィル ビオプロジェ | ヒスタミンh3−受容体リガンドとしての非イミダゾールアルキルアミンと、その治療への応用。 |
JP2003064081A (ja) * | 2001-07-12 | 2003-03-05 | Lab Servier | 新規なオクタヒドロ−2H−ピリド〔1,2−a〕ピラジン化合物、それらの製造方法およびそれらを含む医薬組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015567A1 (en) * | 1991-02-27 | 1992-09-17 | Seed Capital Investment (Sci) B.V. | Imidazole-derivatives having agonistic or antagonistic activity on the histamine h3-receptor |
MXPA03008319A (es) * | 2001-03-16 | 2003-12-11 | Abbott Lab | Nuevas aminas como ligantes del receptor de histamina-3 y sus aplicaciones terapeuticas. |
GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
-
2004
- 2004-04-01 JP JP2005505233A patent/JPWO2004089410A1/ja not_active Withdrawn
- 2004-04-01 CA CA002521000A patent/CA2521000A1/en not_active Abandoned
- 2004-04-01 EP EP04725174A patent/EP1611902A4/en not_active Withdrawn
- 2004-04-01 WO PCT/JP2004/004758 patent/WO2004089410A1/ja not_active Application Discontinuation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002521463A (ja) * | 1998-07-29 | 2002-07-16 | ソシエテ シヴィル ビオプロジェ | ヒスタミンh3−受容体リガンドとしての非イミダゾールアルキルアミンと、その治療への応用。 |
WO2001008705A1 (fr) * | 1999-08-02 | 2001-02-08 | Yamanouchi Pharmaceutical Co., Ltd. | Remedes contre les douleurs neurogenes |
WO2001014383A1 (fr) * | 1999-08-24 | 2001-03-01 | Toray Industries, Inc. | Remedes contre les douleurs neuropathiques et modeles animaux de douleurs neuropathiques |
US20010049367A1 (en) * | 2000-03-09 | 2001-12-06 | Bennani Youssef L. | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
WO2002012214A2 (en) * | 2000-08-08 | 2002-02-14 | Ortho Mcneil Pharmaceutical Inc. | Non-imidazole aryloxyalkylamines as h3 receptor ligands |
WO2002013821A1 (en) * | 2000-08-17 | 2002-02-21 | Gliatech, Inc. | Novel alicyclic imidazoles as h3 agents |
WO2002053153A1 (fr) * | 2000-12-28 | 2002-07-11 | Daiichi Pharmaceutical Co., Ltd. | Medicaments permettant de traiter et de prevenir une douleur neurologique |
JP2003064081A (ja) * | 2001-07-12 | 2003-03-05 | Lab Servier | 新規なオクタヒドロ−2H−ピリド〔1,2−a〕ピラジン化合物、それらの製造方法およびそれらを含む医薬組成物 |
Non-Patent Citations (3)
Title |
---|
FARZIN D. ET AL: "Rodent antinociception following acute treatment with different histamine receptor agonists and antagonists", PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR, vol. 72, 2002, pages 751 - 760, XP002980397 * |
OLSEN U.B. ET AL: "ReN 1869, a novel tricyclic antihistamine, is active against neurogenic pain andinflammation", EUROPEAN J. OF PHARMACOLOGY, vol. 435, 2002, pages 43 - 57, XP002980396 * |
See also references of EP1611902A4 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7396857B2 (en) | 2005-04-22 | 2008-07-08 | Wyeth | Therapeutic combinations for the treatment or prevention of depression |
WO2007043365A1 (ja) * | 2005-10-06 | 2007-04-19 | Japan Science And Technology Agency | 神経因性疼痛治療剤 |
US8569303B2 (en) | 2005-12-29 | 2013-10-29 | Celtaxsys, Inc. | Diamine derivatives as inhibitors of leukotriene A4 hydrolase |
WO2011083316A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives for the treatment of central nervous system disorders |
WO2011083314A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives for the treatment of central nervous system disorders |
WO2011083315A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Compounds and their use |
WO2011121309A1 (en) | 2010-03-31 | 2011-10-06 | Takeda Pharmaceutical Company Limited | Phenyl sulfonyl derivatives and their use as histamine h3 antagonists |
WO2013027001A1 (en) | 2011-08-22 | 2013-02-28 | Takeda Pharmaceutical Company Limited | Compounds and their use to treat histamine h3 related disorders |
US10350197B2 (en) | 2013-03-12 | 2019-07-16 | Celtaxsys, Inc. | Methods of inhibiting leukotriene A4 hydrolase |
US10898471B2 (en) | 2013-03-12 | 2021-01-26 | Celltaxis, Llc | Methods of inhibiting leukotriene A4 hydrolase |
US9777006B2 (en) | 2013-03-14 | 2017-10-03 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
US9856249B2 (en) | 2013-03-14 | 2018-01-02 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
US10501455B2 (en) | 2013-03-14 | 2019-12-10 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
US9822106B2 (en) | 2013-03-14 | 2017-11-21 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
US11053195B2 (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10450269B1 (en) | 2013-11-18 | 2019-10-22 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10898484B2 (en) | 2018-05-31 | 2021-01-26 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
Also Published As
Publication number | Publication date |
---|---|
CA2521000A1 (en) | 2004-10-21 |
JPWO2004089410A1 (ja) | 2006-07-06 |
EP1611902A4 (en) | 2006-04-12 |
EP1611902A1 (en) | 2006-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004089410A1 (ja) | 神経因性疼痛の予防及び/または治療剤 | |
KR100967070B1 (ko) | 아세트산 아닐리드 유도체를 유효성분으로 하는 과활동방광 치료제 | |
TW200829244A (en) | Therapeutic combinations 482 | |
JP5751831B2 (ja) | 鎮痛耐性抑制剤 | |
US20090042883A1 (en) | Antitumor agent | |
WO2009154246A1 (ja) | 勃起不全治療剤 | |
TW201625618A (zh) | 抑制瞬時受體電位a1離子通道 | |
US20230062049A1 (en) | Methods of treating alpha adrenergic mediated conditions | |
WO2012161301A1 (ja) | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 | |
US20090069363A1 (en) | Therapeutic Agent for Constipation | |
US20080299207A1 (en) | Methods and compositions for administration of oxybutynin | |
JP5571072B2 (ja) | アルファアドレナリン介在症状の治療方法 | |
CN102112469B (zh) | 神经元nAChR的安静减敏剂及其使用方法 | |
US8063231B2 (en) | Methods of treating alpha adrenergic mediated conditions | |
WO2010110428A1 (ja) | 掻痒の予防及び/または治療剤 | |
US8168632B2 (en) | Bicyclic amide derivatives for the treatment of respiratory disorders | |
US20240139140A9 (en) | Compositions and methods for stimulating ventilatory and/or respiratory drive | |
US20050065348A1 (en) | Pyridin-2-yl-methylamine derivatives for treating opioid dependence | |
JP4888751B2 (ja) | トリフルオロプロピルアミノペンタン誘導体及びその製造方法 | |
US20200237720A1 (en) | Therapeutic agent for alcohol use disorders | |
TW202342033A (zh) | 用於治療睡眠呼吸中止之α2-腎上腺素受體亞型C(α-2C)拮抗劑與正腎上腺素再吸收抑制劑之組合 | |
TW200906406A (en) | Use of a compound that is a neurokinin A NK2 receptor antagonist for the preparation of medicaments for use in the prevention and treatment of sexual dysfunctions | |
WO2010029996A1 (ja) | 医薬組成物 | |
WO2004013107A1 (ja) | 脊髄損傷による障害の予防及び/又は治療のための医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005505233 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2521000 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004725174 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004725174 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004725174 Country of ref document: EP |